latest update:
[TrialBase DB]

trial summary · NCT07887971

A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

BActinium-2: A Phase 1b, 2 Part, Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Intravenous Administration of a B7-H3 Radiopharmaceutical ([225Ac]Ac AKY 2519) in Participants With B7-H3 Imaging Positive Solid Tumors

Trial record from the TrialBase DB dataset, status RECRUITING, condition NSCLC, sponsored by Aktis Oncology, Inc.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07887971phase PHASE1enrollment 152start 2026-11

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with B7-H3 imaging positive solid tumors.

Source record: https://clinicaltrials.gov/study/NCT07887971

Facts

registry idNCT07887971
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionNSCLC
sponsorAktis Oncology, Inc.
sponsor classINDUSTRY
enrollment152
start date2026-11
primary completion2028-12
completion2033-12
results postednot reported

Conditions

  • NSCLC
  • NSCLC (Advanced Non-small Cell Lung Cancer)
  • ES-SCLC
  • Small Cell Lung Cancer Extensive Stage
  • B7H3
  • Prostate Cancer
  • HNSCC
  • mCRPC (Metastatic Castration-resistant Prostate Cancer)
  • Head Neck Cancer Squamous Cell Metastatic
  • ESCC or Esophageal Adenosquamous Carcinoma
  • CRC
  • CRC (Colorectal Cancer)

Interventions

  • [225Ac]Ac-AKY-2519 (therapeutic)
  • [64Cu]Cu-AKY-2519 (imaging)

Countries

  • United States

Intervention types: DRUG

Work with this record